new pancreatic cancers in the US in 2026

Pancreas and vesselsMapped in every viewEvery contact described
ResectAssist segments the pancreas and the arteries and veins around it, then writes a plain-language note on tumor contact for each vessel, so the team can plan with the full picture.
Resectability depends on how the tumor meets the vessels
of patients are alive five years after diagnosis
are diagnosed after the cancer has spread
have a tumor that surgery can remove at diagnosis
Every vessel gets its own note
ResectAssist segments the pancreas and the arteries and veins around it, color codes each vessel and writes a plain-language note on tumor contact for every one. Every case opens in the axial, coronal, sagittal and 3D views and is described vessel by vessel, in the same order.
Radiologists, surgeons and multidisciplinary teams who plan pancreatic cancer treatment.
- Pancreas
- Superior mesenteric artery
- Celiac axis
- Hepatic artery
- Splenic artery
- Portal and mesenteric veins
ResectAssist
Pancreas resectability
The pancreas and its vessels, mapped in every view.
Whether a pancreatic tumor can be removed depends on how it sits against the nearby blood vessels. ResectAssist segments the pancreas and the arteries and veins around it, then describes the contact for each vessel, so the team can plan with the full picture.
ResectAssist builds on findings like this one. Abdora segments the pancreas and localizes the lesion with the reasoning attached, and ResectAssist adds the surrounding arteries and veins so the team can plan with the full picture.
See vessel by vessel contact on your own pancreas cases.
Bring a recent pancreatic protocol CT and our team will walk through ResectAssist live with your reading team, showing the vessel map and the contact notes for each vessel.
Request a DemoSits on top of your PACS
ResectAssist appears inside the radiologist’s existing reading environment, so the vessel map and the contact notes are available where the scan is already read. The radiologist reviews and signs off on each description, and the tumor board makes the planning decision. No separate viewer, no extra logins, no workflow rebuild.
- DICOM-native, vendor-neutral
- On-prem, cloud, or hybrid deployment